Does hormone replacement therapy benefit post-menopausal women? – a scoping review

• Autorzy: Mugada V. , Kolakota R.K. , Jadda S.B. , Kotapadu U. , Vessam M.
• Języki publikacji: EN

Abstrakty

EN

Post-menopausal women experience symptoms such as irregular periods, lower fertility, vaginal dryness, hot flashes and night sweats. Hormone replacement therapy (HRT) relieves menopausal symptoms. The aim of this review was to assess the benefits and risks of HRT in post-menopausal women. A scoping review was conducted for original peer-reviewed English language papers using the electronic databases of PUB MED, JAMA, BMC and TRIP. The papers were subjected to a three-stage screening process. The type of study, year of study, age, participants, type of therapy and the aim of the study defined the inclusion and exclusion criteria. HRT was associated with reduced risk and prevalence of end-stage kidney disease, gastric esophageal reflex disease (GORD) symptoms, periodontal disease and associated with the increased risk of overall cancers. The benefits of HRT depend on the duration of therapy, formulation, route of administration, time of initiating therapy (age <60 years) and type of therapy. Post-menopausal symptomatic women mostly benefited with hormone replacement therapy. To reduce risks of adverse events, HRT should be initiated with appropriate monitoring.

• Wydawca: -
• Czasopismo: Medical Science Pulse
• Rocznik: 2019
• Tom: 13
• Numer: 2
• Opis fizyczny: p.52-57,ref.

Twórcy

autor

Mugada V.

• Department of Pharmacy Practice, Vignan Institute of Pharmaceutical Technology, Duvvada, AP, India

autor

Kolakota R.K.

• Department of Pharmacy Practice, Vignan Institute of Pharmaceutical Technology, Duvvada, AP, India

autor

Jadda S.B.

• Department of Pharmacy Practice, Vignan Institute of Pharmaceutical Technology, Duvvada, AP, India

autor

Kotapadu U.

• Department of Pharmacy Practice, Vignan Institute of Pharmaceutical Technology, Duvvada, AP, India

autor

Vessam M.

• Department of Pharmacy Practice, Vignan Institute of Pharmaceutical Technology, Duvvada, AP, India

Bibliografia

• 1. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005; 3: 47.
• 2. Shyu YK, Pan CH, Liu WM, Hsueh JY, Hsu CS, et al. Healthrelated quality of life and healthcare resource utilization in Taiwanese women with menopausal symptoms: a nation-wide survey. J Nurs Res 2012; 20(3): 208–218.
• 3. Nordqvist C, Brito J. Everything you need to know about menopause [online] 2017 [cit. 10.12. 2018]. Available from URL: https://www.medicalnewstoday.com/articles/155651.php.
• 4. Caufriez A. Hormonal replacement therapy (HRT) in post-menopause: a reappraisal. Ann Endocrinol (Paris) 2007 Sep; 68(4): 241–250.
• 5. Harman SM. Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEE PS. Gend Med 2006; 3: 254–269.
• 6. Ettinger B, Friedman GD, Bush T, Queensberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996; 87(1): 6–12.
• 7. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, et al. Postmenopausal hormone therapy and mortality. N Eng J Med 1997; 336(25): 1769–1775.
• 8. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362(9382): 428–432.
• 9. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progesterone: the ESTHER study. Circulation 2007; 115(7): 840–845.
• 10. Kiel DP, Felson DT, Andersen JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. The Framingham study. N Eng J Med 1987; 317(19): 1169–1174.
• 11. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Preventive Med 1991; 20(1): 47–63.
• 12. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177–188.
• 13. Hulley S, Grady D, Bush T, Furberg C, Herrington D, et al. For the heart and estrogen-progesterone replacement study (HERS) research group randomized trial of estrogen plus progesterone for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Association 1998; 280(7); 605–613.
• 14. Zweifel J, O’Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychneuroendocrinology 1997; 22(3): 189–212.
• 15. Sarrel PM. Effects of hormone replacement therapy on sexual psychophysiology and behaviour in post-menopause. J Womens Health Gend Based Med 2000; 9 Suppl 1: 525–532.
• 16. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer’s disease in women. Am J Epidemiol 1994; 140(3): 256–261.
• 17. Welton AJ, Vickers MR, Kim J, Ford D, Lawton BA , et al. Healthrelated quality of life after combined hormone replacement therapy: randomized controlled trial. BMJ 2008; 337: a1190.
• 18. Cardozo L, Bachmann G, MC Clish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy I the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecology 1998; 92(4 pt 2): 722–727.
• 19. Carrasquilla GD, Frumento P, Berglund A, Brogfeldt C, Bottai M, et al. Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies. PLoS Med 2017; 14(11): e1002445.
• 20. Simin J, Tamimi R, Lagergren J, Adami HO, Brusselaers N. Menopausal hormone therapy and cancer risk: An overestimated risk? European Journal of Cancer 2017; 84: 60–68.
• 21. Hale GE, Shufelt CL. Hormone therapy in menopause: an update on cardiovascular disease considerations. Trends Cardiovasc Med 2015; 25(6): 540–549
• 22. Gleason CE, Dowling NM, Wharton W, Manson JE, Miler VM, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled keeps–cognitive and effective study. Plos Med 2015; 12(6): e1001833.
• 23. Close H, Mason JM, Wilson D, Hungin AP. Hormone replacement therapy is associated with gastro-oesophageal reflux disease: a retrospective cohort study. BMC Gastroenterology 2012; 12: 56.
• 24. Evalt M, Musante ML, Weiner W, Pabst K, Dustin K, et al. A randomized pilot trial of estrogen replacement therapy in post-menopausal women with Parkinson’s disease. Elsevier 2011; 17(10): 757–760.
• 25. Canonico M, Fournier A, Carcaillon L. Olie V, Oger E, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010 Feb; 30(2): 340–345.
• 26. Tarkkila L, Kari K, Furuholm J, Aila T, Jukka HM. Periodontal disease-associated micro-organisms in peri-menopausal and post-menopausal women using or not using hormone replacement therapy: a two-year follow-up study. BMC Oral Health 2010; 10(1): 10.
• 27. Vickers MR, Martin J, Meade TW. The women’s international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial. BMC Womens Health 2007; 7(2): 1–17.
• 28. Seed M, Sands RH, Mc Laren M, Kirk G, Darko D. The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post-menopausal women. Family Practise 2000; 17(6): 479–507.
• 29. Payne JB, Zachs NR, Reinhardt RA, Nummikoski PV, Patil KD. The association between estrogen status and alveolar bone density changes in postmenopausal women with a history of periodontitis. Periodontology 1997: 68(1): 24–31.
• 30. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321–333.
• 31. Forabosco A, Criscuolo M, Coukos G, Ucelli E, Weinstein R, et al. Efficacy of hormone replacement therapy in postmenopausal women with oral discomfort. Oral Surg Oral Med Oral Pathol 1992 May; 73(5): 570–574.
• 32. Boardman HM, Hartley L, Eisinga A, Main C, Roque I, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015; 10(3): CD002229.
• 33. White H, Murin S. Is the current classification of venous thromboembolism acceptable? No. J Thromb Haemost 2004; 2(12): 2262–2263.
• 34. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291(14): 1701–1712.
• 35. Dumanski SM, Ramesh S, James MT, Metcalfe A, Nerenberg K, et al. The effect and safety of postmenopausal hormone therapy and selective estrogen receptor modulators on kidney outcomes in women: a protocol for systematic review and meta-analysis. Systematic Reviews 2017; 6(1): 134.
• 36. Chlebowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, et al. Breast cancer after use of estrogen plus progestin and estrogen alone, analyses of data from 2 women’s health initiative randomized clinical trials. JAMA Oncology 2015; 1(3): 296–305.
• 37. Tranah GJ, Parimi N, Blackwell T, Ancoli-Israel S, Ensrud KE, et al. Postmenopausal hormones and sleep quality in the elderly: a population-based study. BMC Womens Health 2010; 10: 15.
• 38. Collaborative Group On Epidemiological Studies Of Ovarian Cancer, Beral V, Gaitskell K, Hermon C, Moser K, et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015 May 9; 385(9980): 1835–1842.
• 39. Nordenvall C, Oskarsson V, Sadt-Azodi O, Orsini N, Wolk A. Postmenopausal hormone replacement therapy and risk of cholecystectomy: a prospective cohort study. Scand J Gastroenterol 2014 Jan; 49(1): 109–113.
• 40. Farhat GN, Parimi N, Chelbowski RT, JoAnn E, Garnet A, et al. Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst 2013; 105(19): 1496–1503.
• 41. Engel P, Fabre A, Fournier A, Mesrine S, Boutron-Ruault MC, et al. Risk of osteoporotic fractures after discontinuation of menopausal hormone therapy: results from the E3N cohort. Am J Epidemiol 2011; 174(1): 12–21.
• 42. Cravioto MD, Durand-Carbajal M, Jimenez-Santana L, Lara-Reyes P, Seuc AH, et al. Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematous: a randomized, double-blind, controlled trial. Arthritis Care Res (Hoboken) 2011 Dec; 63(12): 1654–1663.
• 43. Cirillo DJ, Wallace RB, Rodabough RJ, Greenland P, Lacroix AZ et al. Effect of estrogen therapy on gallbladder disease. JAMA 2005; 293: 330–339.
• 44. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, et al. Conjugated Equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women, women’s health initiative memory study. JAMA 2004; 291(24): 2947–2958.
• 45. Nelson HD, Rizzo J, Harris E, Cauley J, Ensrud K, et al. Osteoporosis and fractures in postmenopausal women using estrogen. Arch Intern Med 2002; 162(20): 2278–2284.

Identyfikatory

DOI

10.5604/01.3001.0013.1367